The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ALS and acquired Mexico City-based ARJ
  • ARJ is the largest, private pharmaceutical testing lab in Latin America
  • Mexico is a growing contributor to the $20 billion global pharmaceutical testing market and an important hub for Latin and North America
  • ALS states the acquisition of ARJ supports its strategy focusing on food and pharmaceutical opportunities in key growth markets such as Latin America

Brisbane-based ALS has acquired Laboratorios de Control ARJ (ARJ).

ALS is a leading testing, inspection, certification and verification company trying to expand its global presence.

Based in Mexico City, ARJ is the largest, private pharmaceutical testing lab in Latin America with revenues of over $30 million.

ARJ was founded in 1967 and has steadily grown its business, employing over 500 people. It specialises in providing quality control for medicines, biological products, generics, biosimilars, cosmetics and medical devices. It also services many of the world’s largest pharmaceutical companies.

Mexico is a growing contributor to the $20 billion global pharmaceutical testing market and an important hub for Latin and North America.

“ARJ has a world class operation and client base which offers us a strong platform to continue to grow our presence in key markets including Argentina, Brazil, Colombia, and Mexico. We welcome the ARJ team to ALS and look forward to our collaboration with them throughout the region,” ALS Managing Director and CEO Raj Naran said.

ALS’ acquisition of ARJ is supported by the company’s existing Life Sciences Latin America operations and is expected to benefit from Group’s regional and global presence to further expand their offerings to clients.

“The acquisition of ARJ aligns with our stated acquisition strategy focusing on food and pharmaceutical opportunities in key growth markets such as Latin America,” Raj said.

ALQ by the numbers
More From The Market Online
Medical project manager using a laptop

Dimerix signs up first patient for ‘highly significant’ paediatric clinical trial

Dimerix Limited (ASX:DXB), a Melbourne-based biopharmaceutical company, has started recruitment for its first paediatric patient for the Phase 3 ACTION3
Free radicals

Publication highlights strengths of Memphasys’ antioxidant profiling system

Memphasys Ltd has seen a positive focus on its RoXsta antioxidant profiling system, through the publication…
A toilet in an abandoned spot

Immuron progresses development of traveller’s diarrhea drug Travelan

Immuron Ltd has presented a Clinical Study Report to the US Food and Drug Administration following…
Monoclonal antibodies

Telix takes on ‘next-gen’ cancer drug candidates through $372m asset buy

Telix Pharmaceuticals Ltd has entered an asset purchase agreement with antibody engineering company ImaginAb, Inc